Access To Patents
-
{
- All
- News
- Videos
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Palworld to Exit Early Access, Get Version 1.0 Release in 2026, Pocketpair Announces
Palworld is set to exit early access and get a full version 1.0 release next year. Developer Pocketpair said update 1.0 was in development. The studio said it would address Palworld's "quirks and janks" before releasing version 1.0. The company also said it would release the game's winter update later this year.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Palworld to Exit Early Access, Get Version 1.0 Release in 2026, Pocketpair Announces
Palworld is set to exit early access and get a full version 1.0 release next year. Developer Pocketpair said update 1.0 was in development. The studio said it would address Palworld's "quirks and janks" before releasing version 1.0. The company also said it would release the game's winter update later this year.
